offline roulette game

offline roulette game

For fans of Jay Chou, known for his soul-stirring ballads and dynamic stage presence, the opportunity to see him live in concert is a dream come true. With his unique blend of Mandopop, R&B, and hip-hop influences, Jay Chou has captivated audiences for over two decades, earning a dedicated fan base that spans across generations.

In conclusion, while the issue of LeBron James' playing time may be a subject of debate among foreign media, one thing is certain – his impact on the game and his ability to defy age and expectations will continue to fascinate and inspire basketball fans around the world.

SUZHOU, China, Nov. 27, 2024 (GLOBE NEWSWIRE) -- YXT.com Group Holding Limited YXT ("YXT.com" or the "Company"), a leader and disruptor of the digital corporate learning industry in China, today announced its unaudited financial results for the first nine months of 2024 that ended September 30, 2024. First Nine Months 2024 Operating and Financial Highlights Total revenues were RMB241.7 million (US$34.4 million), compared with RMB328.8 million in the same period of last year. Gross Margin was 60.4% in the nine months ended September 30, 2024, compared with 59.3% in the same period of last year. Net loss was RMB14.9 million (US$2.1 million), compared with RMB245.3 million in the same period of last year. Number of subscription customers decreased to 2,428 as of September 30, 2024, from 3,039 as of September 30, 2023. After adjusting for the deconsolidation of CEIBS Publishing Group Limited (the "CEIBS PG") (571 customers), the net change of 40 customers reflects the Company's strategic shift toward large enterprise accounts with consistent demand for corporate learning solutions. This realignment resulted in a planned reduction of small and medium-sized customers from our portfolio. Net revenue retention rates of subscription customers decreased to 101.0% from 104.8% in the same period of last year. The change was due to the Company's strategic shift toward large enterprise accounts with consistent demand for corporate learning solutions. This realignment resulted in a planned reduction of small and medium-sized customers from our portfolio. Mr. Xiaoyan Lu, Director, Founder and Chairman of the Board of YXT.com, commented, "We are pleased to report our first financial results as a public company, covering the nine months ended September 30, 2024, following our successful IPO on the Nasdaq in August. While the period presented macro challenges that impacted enterprise training spending, we remained focused on executing our strategic priorities. We continued to deepen our relationships with large enterprise clients, as evidenced by our growing penetration among Fortune 500 companies. Our products' new AI features have been well-received by key customers, enabling us to maintain healthy retention rates despite the challenging environment. Looking ahead, we remain cautiously optimistic about our long-term growth prospects, supported by the fundamental need for digital learning solutions, our strengthening position in the large enterprise segment, and our continuous product innovation and enhancement." Mr. Pun Leung Liu, Chief Financial Officer of YXT.com, added, "Our financial results for the first nine months of 2024 demonstrate the effectiveness of our operational optimization initiatives. Through strategic cost management and AI-enabled operational improvements across multiple functions, we significantly narrowed our net loss to RMB14.9 million from RMB245.3 million in the same period last year. We remain committed to disciplined cost control while continuing to invest in strategic areas that drive long-term growth, particularly our technology capabilities and enterprise-focused solutions." Financial Results for the First Nine Months of 2024 Revenues Revenues were RMB241.7 million (US$34.4 million), compared with RMB328.8 million in the same period of last year. Revenues from corporate learning solutions were RMB240.3 million (US$34.2 million), compared with RMB318.6 million in the same period of last year. Revenues from subscription based corporate learning solutions were RMB221.7 million (US$31.6 million), compared with RMB271.1 million in the same period of last year. The change was primarily due to (i) the deconsolidation of CEIBS PG effective on January 15, 2024, resulting in a decrease of RMB46.1 million; and (ii) a net impact of RMB3.3 million from operational adjustments, driven by our strategic suspension of certain ancillary online teaching tools, partially offset by growth in corporate learning platform services. Revenues from non-subscription based corporate learning solutions were RMB18.6 million (US$2.7 million), compared with RMB47.5 million in the same period of last year. The change was primarily due to (i) the deconsolidation of CEIBS PG effective on January 15, 2024, resulting in a decrease of RMB20.9 million; and (ii) reduced offline activities reflecting our strategic shift towards subscription-based corporate learning solutions. Revenues from others were RMB1.4 million (US$0.2 million), compared with RMB10.2 million in the same period of last year. The change primarily reflects fewer customized software projects completed in the nine months ended September 30, 2024, aligning with our strategic focus on corporate learning solutions. Cost of revenues Cost of revenues was RMB95.8 million (US$13.6 million), compared with RMB133.8 million in the same period of 2023, representing a decrease of 28.4%, mainly due to (i) the deconsolidation of CEIBS PG effective on January 15, 2024, resulting in a decrease of RMB22.7 million; (ii) lower instructor compensation costs due to reduced offline activities, aligning with our strategic shift towards subscription-based corporate learning solutions; and (iii) decreased staff expenses and third-party infrastructure costs through operational optimization. Sales and marketing expenses Sales and marketing expenses were RMB105.8 million (US$15.1 million), compared with RMB173.2 million in the same period of last year, representing a decrease of 38.9%, mainly due to (i) the deconsolidation of CEIBS PG effective on January 15, 2024, resulting in a decrease of RMB36.5 million; and (ii) reduced compensation and incentives through human resources optimization. Research and development expenses Research and development expenses were RMB90.6 million (US$12.9 million), compared with RMB136.8 million in the same period of 2023, representing a decrease of 33.8%, mainly due to (i) the deconsolidation of CEIBS PG effective on January 15, 2024, resulting in a decrease of RMB18.8 million; and (ii) reduced compensation through human resources optimization. General and administrative expenses General and administrative expenses were RMB75.0 million (US$10.7 million), compared with RMB117.1 million in the same period of 2023, representing a decrease of 35.9%, mainly due to (i) the deconsolidation of CEIBS PG effective on January 15, 2024, resulting in a decrease of RMB13.5 million; (ii) a RMB18.5 million decrease in share-based compensation following completion of certain share-based incentives amortization; and (iii) reduced professional fees. Net loss and adjusted net loss Net loss was RMB14.9 million (US$2.1 million), compared with a net loss of RMB245.3 million in the same period of last year. Adjusted net loss was RMB123.1 million (US$17.5 million), compared with an adjusted net loss of RMB196.1 million in the same period of last year. Earnings/(loss) per share Basic and diluted net income per share was RMB5.02 (US$0.72), compared with basic and diluted net loss per share of RMB7.06 in the same period of last year. The improvement in earnings per share was primarily attributable to the deemed contribution to common shareholders due to modification and extinguishment of the Company's convertible redeemable preferred shares on July 1, 2024. Balance Sheet As of September 30, 2024, the Company had cash and cash equivalents, restricted cash, short-term investments and long-term bank deposits of RMB488.7 million (US$69.6 million), compared with RMB496.2 million as of December 31, 2023. Conference Call Information The Company's management team will hold a conference call at 8:00 P.M. U.S. Eastern Time on Tuesday, November 26, 2024 (or 9:00 A.M. Beijing Time on Wednesday, November 27, 2024) to discuss the financial results. Details for the conference call are as follows: Event Title: YXT.com First Nine Months of 2024 Earnings Conference Call Registration Link: https://register.vevent.com/register/BI79cfe397cd984d14b7a1fab15a19b825 All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers and a unique access PIN, which can be used to join the conference call. A live and archived webcast of the conference call will be available at the Company's investor relations website at https://ir.yxt.com/ . Non-GAAP Financial Measures In evaluating our business, we consider and use adjusted net loss as a supplemental non-GAAP measure to review and assess our operating performance. Adjusted net loss is net loss excluding amortization of incremental intangible assets resulting from business combination, gain on deconsolidation of CEIBS PG, share-based compensation, change in fair value of derivative liabilities, net of income taxes, to the extent applicable. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We present the non-GAAP financial measure because it is used by our management to evaluate our operating performance and formulate business plans. We also believe that the use of the non-GAAP measure facilitates investors' assessment of our operating performance. The non-GAAP financial measure is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. The non-GAAP financial measure has limitations as analytical tools. One of the key limitations of using the non-GAAP financial measure is that it does not reflect all items of income and expense that affect our operations. Further, the non-GAAP measure may differ from the non-GAAP information used by other companies, including peer companies, and therefore its comparability may be limited. We compensate for these limitations by reconciling the non-GAAP financial measure to the nearest U.S. GAAP performance measure, which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure. Exchange Rate Information This announcement contains translations of certain Renminbi ("RMB") amounts into U.S. dollars ("US$") at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from Renminbi to U.S. dollars were made at the rate of RMB7.0176 to US$1.00, the exchange rate on September 30, 2024, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred to could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. Safe Harbor Statements This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to", or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. About YXT.com As a technology company, YXT.com provides corporations with digital corporate learning solutions, including SaaS platforms, learning content, and other services. YXT.com is a leader and disruptor of the digital corporate learning industry in China. Established in 2011, YXT.com has supported Fortune 500 companies and other leading companies with their transformation and digitalization of learning and development, and has received recognition, respect and recurring business. Contact Robin Yang ICR, LLC YXT.IR@icrinc.com +1 (646) 405-4883 YXT.COM GROUP HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND SEPTEMBER 30, 2024 (All amounts in thousands, except for share and per share data, unless otherwise noted) As of December 31, As of September 30, 2023 2024 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 320,489 488,464 69,606 Restricted Cash - 257 37 Short-term investments 58,128 - - Accounts receivable, net 32,790 19,392 2,763 Prepaid expenses and other current assets 12,028 18,361 2,616 Amounts due from related parties - 7,000 997 Total current assets 423,435 533,474 76,019 Non-current assets: Property, equipment and software, net 23,402 16,085 2,292 Intangible assets, net 12,720 8,887 1,266 Goodwill 164,113 163,837 23,347 Long-term investments 126,341 116,693 16,629 Operating lease right-of-use assets, net 34,997 20,337 2,898 Other non-current assets 22,265 11,760 1,676 Long-term bank deposits 117,573 - - Total non-current assets 501,411 337,599 48,108 Total assets 924,846 871,073 124,127 LIABILITIES, MEZZANINE AND SHAREHOLDERS' DEFICIT Current liabilities Accounts payable 17,855 8,528 1,215 Amounts due to related parties - 3,155 450 Short-term borrowings 46,800 179,000 25,507 Deferred revenue, current 188,485 101,276 14,432 Acquisition consideration payable 14,775 14,775 2,105 Other payable and accrued liabilities 89,937 73,150 10,425 Derivative liabilities 100,279 - - Operating lease liabilities, current 15,818 6,629 945 Total current liabilities 473,949 386,513 55,079 Non-current liabilities Long-term borrowings 219,000 128,000 18,240 Operating lease liabilities, non-current 20,257 12,191 1,737 Deferred revenue, non-current 58,952 56,038 7,985 Total non-current liabilities 298,209 196,229 27,962 Total liabilities 772,158 582,742 83,041 YXT.COM GROUP HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND SEPTEMBER 30, 2024 (All amounts in thousands, except for share and per share data, unless otherwise noted) As of December 31, As of September 30, 2023 2024 RMB RMB US$ Mezzanine equity Series A convertible redeemable preferred shares (US$0.0001 par value, 15,040,570 and nil shares authorized, issued and outstanding as of December 31, 2023 and September 30, 2024) 408,139 - - Series B convertible redeemable preferred shares (US$0.0001 par value, 7,085,330 and nil shares authorized, issued and outstanding as of December 31, 2023 and September 30, 2024) 199,518 - - Series C convertible redeemable preferred shares (US$0.0001 par value, 23,786,590 and nil shares authorized, issued and outstanding as of December 31, 2023 and September 30, 2024) 493,788 - - Series D convertible redeemable preferred shares (US$0.0001 par value, 37,152,161 and nil shares authorized, issued and outstanding as of December 31, 2023 and September 30, 2024) 1,059,434 - - Series E convertible redeemable preferred shares (US$0.0001 par value, 26,417,318 and nil shares authorized, issued and outstanding as of December 31, 2023 and September 30, 2024) 1,402,802 - - Total mezzanine equity 3,563,681 - - Shareholders' (deficit)/equity Ordinary shares (US$0.0001 par value 390,518,031 and 500,000,000 shares authorized as of December 31, 2023 and September 30, 2024, respectively; 48,253,425 and 180,226,597 shares issued and outstanding as of December 31, 2023 and September 30, 2024, respectively) 33 129 18 Additional paid-in capital 16,671 3,968,966 565,573 Statutory reserve 4,322 - - Accumulated other comprehensive income 23,775 9,989 1,423 Accumulated deficit (3,490,681 ) (3,690,753 ) (525,928 ) Total YXT.COM Group Holding Limited shareholders' (deficit)/equity (3,445,880 ) 288,331 41,086 Non-controlling interests 34,887 - - Total shareholders' (deficit)/equity (3,410,993 ) 288,331 41,086 Total liabilities, mezzanine equity and shareholders' (deficit)/equity 924,846 871,073 124,127 YXT.COM GROUP HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS)/INCOME FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2024 (All amounts in thousands, except for share and per share data, unless otherwise noted) For the nine months ended September 30, 2023 2024 RMB RMB US$ Revenues: Corporate learning solutions 318,656 240,286 34,240 Others 10,174 1,439 206 Total revenues 328,830 241,725 34,446 Cost of revenues (133,819 ) (95,785 ) (13,649 ) Sales and marketing expenses (173,241 ) (105,822 ) (15,080 ) Research and development expenses (136,784 ) (90,606 ) (12,911 ) General and administrative expenses (117,087 ) (75,039 ) (10,694 ) Other operating income 5,171 6,461 921 Loss from operations (226,930 ) (119,066 ) (16,967 ) Interest and investment income 3,608 5,105 728 Interest expense (2,831 ) (7,866 ) (1,121 ) Investment losses (6,134 ) (6,153 ) (877 ) Gain on deconsolidation of CEIBS Publishing Group - 78,760 11,223 Foreign exchange loss, net (274 ) (39 ) (6 ) Change in fair value of derivative liabilities (16,200 ) 34,378 4,899 Loss before income tax expense (248,761 ) (14,881 ) (2,121 ) Income tax benefit 3,461 - - Net loss (245,300 ) (14,881 ) (2,121 ) Net loss attributable to non-controlling interests shareholders 5,629 300 43 Net loss attributable to YXT.COM Group Holding Limited (239,671 ) (14,581 ) (2,078 ) YXT.COM GROUP HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS)/INCOME FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2024 (All amounts in thousands, except for share and per share data, unless otherwise noted) For the nine months ended September 30, 2023 2024 RMB RMB US$ Net loss attributable to YXT.COM Group Holding Limited (239,671 ) (14,581 ) (2,078 ) Net accretion of convertible redeemable preferred shares (103,840 ) (290,543 ) (41,402 ) Deemed contribution to common shareholders due to modification and extinguishment - 672,170 94,783 Deemed dividend to preferred shareholders due to modification - (5,940 ) (846 ) Net (loss)/income attributable to ordinary shareholders of YXT.COM Group Holding Limited (343,511 ) 361,106 51,457 Net loss (245,300 ) (14,881 ) (2,121 ) Other comprehensive (loss)/income Foreign currency translation 4,951 (4,715 ) (671 ) Unrealized gain/(loss) on investments in available-for-sale debt securities, net of tax 2,923 (9,071 ) (1,293 ) Total comprehensive loss (237,426 ) (28,667 ) (4,085 ) Total comprehensive loss attributable to non-controlling interests 5,629 300 42 Total comprehensive loss attributable to YXT.COM Group Holding Limited (231,797 ) (28,367 ) (4,042 ) Net (loss)/income attributable to ordinary shareholders of YXT.COM Group Holding Limited (343,511 ) 361,106 51,457 —Weighted average number of ordinary shares basic and diluted 48,629,814 72,004,696 72,004,696 Net (loss)/income per share attributable to ordinary shareholders: —Basic and diluted (7.06 ) 5.02 0.72 YXT.COM GROUP HOLDING LIMITED UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2024 (All amounts in thousands, except for share and per share data, unless otherwise noted) For the nine months ended September 30, 2023 2024 RMB RMB US$ Net loss (245,300 ) (14,881 ) (2,121 ) Adjustments: Amortization of incremental intangible assets resulting from business combination 12,730 - - Gain on deconsolidation of CEIBS Publishing Group - (78,760 ) (11,222 ) Share-based compensation 23,423 4,915 700 Change in fair value of derivative liabilities 16,200 (34,378 ) (4,899 ) Adjusted loss before income taxes (192,947 ) (123,104 ) (17,542 ) Adjusted income taxes (3,183 ) - - Adjusted net loss (196,130 ) (123,104 ) (17,542 ) © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenWith Manchester United opting to go without a sporting director and Arsenal targeting Ashworth, the landscape of Premier League football looks set for a shake-up. As both clubs look to navigate the challenges of the modern game and position themselves for success, the coming months promise to be crucial in shaping their respective futures.

As we reflect on this heartening tale of reunion and resilience, let us be inspired to follow in the footsteps of the dedicated volunteer who helped make it all possible. May we each strive to embody the values of empathy, determination, and community spirit in our own lives, knowing that small acts of kindness can have a ripple effect that reaches far beyond our wildest dreams.The swift action taken to withdraw the chief prosecutor's resume indicates that the authorities are taking the allegations seriously and are looking to distance themselves from the scandal. However, the lack of an official response from the government has left many unanswered questions and fueled speculation about the extent of the chief prosecutor's involvement in the illicit activities.

China's Foreign Trade Shows Resilience with 4.9% Year-on-Year Growth in the First 11 Months

Smokers who quit for a week could save a day of their life, experts say

Intel CEO Gelsinger steps down as chipmaking giant strugglesIn essence, the appeal of Qiong Yao dramas for the younger generation lies in their ability to transport viewers to a world where love is pure, emotions run deep, and happy endings are always possible. By embracing the romanticism and melodrama of these classic Taiwanese dramas, young people are finding a sense of comfort and emotional release in a fast-paced and chaotic world.Men lose 17 minutes of life with every cigarette they smoke while a woman’s life is cut short by 22 minutes with each cigarette, experts have estimated. This is more than previous estimates, which suggest that each cigarette shortens a smoker’s life by 11 minutes. The new estimates, which suggest that each cigarette leads to 20 minutes loss of live on average across both genders, are based on more up-to-date figures from long-term studies tracking the health of the population. Researchers from University College London said that the harm caused by smoking is “cumulative” and the sooner a person stops smoking, and the more cigarettes they avoid smoking, the longer they live. The new analysis, commissioned by the Department for Health and Social Care, suggests that if a 10-cigarettes-a-day smoker quits on January 1, then by January 8 they could “prevent loss of a full day of life”. By February 20, their lives could be extended by a whole week. And if their quitting is successful until August 5, they will likely live for a whole month longer than if they had continued to smoke. The authors added: “Studies suggest that smokers typically lose about the same number of healthy years as they do total years of life. “Thus smoking primarily eats into the relatively healthy middle years rather than shortening the period at the end of life, which is often marked by chronic illness or disability. “So a 60-year-old smoker will typically have the health profile of a 70-year-old non-smoker.” The analysis, to be published in the Journal of Addiction, concludes: “We estimate that on average, smokers in Britain who do not quit lose approximately 20 minutes of life expectancy for each cigarette they smoke. “This is time that would likely be spent in relatively good health. “Stopping smoking at every age is beneficial but the sooner smokers get off this escalator of death the longer and healthier they can expect their lives to be.” Dr Sarah Jackson, principal research fellow from the UCL Alcohol and Tobacco Research Group, said: “It is vital that people understand just how harmful smoking is and how much quitting can improve their health and life expectancy. “The evidence suggests people lose, on average, around 20 minutes of life for each cigarette they smoke. “The sooner a person stops smoking, the longer they live. “Quitting at any age substantially improves health and the benefits start almost immediately. “It’s never too late to make a positive change for your health and there are a range of effective products and treatments that can help smokers quit for good.” Health officials have said that smokers can find advice, support and resources with the NHS Quit Smoking app, as well as the online Personal Quit Plan. Public health minister Andrew Gwynne said: “Smoking is an expensive and deadly habit and these findings reveal the shocking reality of this addiction, highlighting how important it is to quit. “The new year offers a perfect chance for smokers to make a new resolution and take that step.” Commenting on the paper, Professor Sanjay Agrawal, special adviser on tobacco at the Royal College of Physicians, said: “Every cigarette smoked costs precious minutes of life, and the cumulative impact is devastating, not only for individuals but also for our healthcare system and economy. “This research is a powerful reminder of the urgent need to address cigarette smoking as the leading preventable cause of death and disease in the UK.”

In conclusion, the stock market's recent surge with 100 stocks hitting the daily limit-up demonstrates the excitement and opportunities present in the equity market. While this bullish momentum is a reflection of positive economic indicators and investor sentiment, it is also essential for investors to exercise prudence and risk management to navigate the challenges and uncertainties that lie ahead. With careful planning and a disciplined approach, investors can make the most of the current market conditions while safeguarding their investments for the long term.The Washington Commanders secured a play-off spot after beating the Atlanta Falcons 30-24 in overtime. Rookie quarterback Jayden Daniels rushed for 127 yards, throwing for another 227 and for three touchdowns, including the game-winning touchdown pass to Zach Ertz. The Commanders staged a dramatic comeback from a 10-point deficit at half-time, sending them to the play-offs for the first time in four years. PLAYOFF BOUND!!!!!!!!!!!! pic.twitter.com/djmqZv3kH6 — Washington Commanders (@Commanders) December 30, 2024 The win was enough to give the Los Angeles Rams the NFC West title as it ended the Seattle Seahawks hopes ahead of their meeting in the final week of the season. The Falcons need other results to go their way along with a win over the Carolina Panthers in their final game. Saquon Barkley became the ninth running back in NFL history to rush for 2,000 yards in a single season as the Philadelphia Eagles clinched the NFC East title with a victory over the Dallas Cowboys. The 27-year-old achieved the feat with a 23-yard run during the fourth quarter of the Eagles’ crushing 41-7 success at Lincoln Financial Field. Barkley is 100 yards short of Eric Dickerson’s record of 2,105 yards, set in 1984 for the Los Angeles Rams, ahead of next week’s regular season finale against the New York Giants. Single-season rushing record in reach. @saquon @Eagles pic.twitter.com/iSHyXeMLv1 — NFL (@NFL) December 29, 2024 However, he could be rested for that game in order to protect him from injury ahead of the play-offs. The Minnesota Vikings scored their ninth consecutive win after hanging on to beat the Green Bay Packers 27-25. Sam Darnold threw touchdowns to Cam Akers, Jordan Addison and Jalen Nailer, pushing his total for the season to 35. The victory set up a final-week showdown with the Detroit Lions for both the division title and top seed in the NFC. The Miami Dolphins kept themselves in the play-off race with a 20-3 victory over the Cleveland Browns. With Dolphins’ quarterback Tua Tagovailoa out with a hip injury, replacement Tyler Huntly threw for 225 yards and a touchdown. he BAKED today 👨‍🍳 pic.twitter.com/eFX9fd1w5P — NFL (@NFL) December 29, 2024 Miami will need to beat the New York Jets and hope the Denver Broncos lose to the Kansas City Chiefs to clinch the final AFC wildcard berth. The Tampa Bay Buccaneers kept alive their dreams of reaching the play-offs by overcoming the Carolina Panthers 48-14. Veteran quarterback Baker Mayfield produced a dominant performance at Raymond James Stadium, registering five passing touchdowns to equal a Buccaneers franchise record. The Buffalo Bills clinched the AFC conference number two seed for the post season with a 40-14 success over the New York Jets at Highmark Stadium. Josh Allen passed for 182 yards and two touchdowns, while rushing for another. Buffalo finish the 2024 regular season undefeated at home, with eight wins from as many games. The Indianapolis Colts’ hopes of reaching the play-offs were ended by a 45-33 defeat to the Giants. FINAL: Drew Lock accounts for 5 TDs in the @Giants victory! #INDvsNYG pic.twitter.com/N8HJYth09F — NFL (@NFL) December 29, 2024 Malik Nabers exploded for 171 yards and two touchdowns and Ihmir Smith-Marsette broke a 100-yard kick-off return to give the Giants their highest-scoring output under head coach Brian Daboll. Quarterback Drew Lock threw four touchdown passes and accounted for a fifth on the ground to seal the win. Elsewhere, Mac Jones threw two touchdowns to help the Jacksonville Jaguars defeat the Tennessee Titans 20-13, while the Las Vegas Raiders beat the New Orleans Saints 25-10. We do not moderate comments, but we expect readers to adhere to certain rules in the interests of open and accountable debate.